HPC Biosciences Ltd Stock Price Today (NSE: HPBL)

HPC Biosciences Ltd

248.002.00 (0.80%)
Market Closed

Fundamental Score

...

HPC Biosciences Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis

HPC Biosciences Ltd share price today is 248.00, down 0.80% on NSE/BSE as of 19 June 2026. HPC Biosciences Ltd (HPBL) is a Small-cap company in the Packaging sector with a market capitalisation of 204.16 (Cr). The 52-week high for HPBL share price is 284.45 and the 52-week low is 140.10. At a P/E ratio of 14.07x, HPBL is currently trading below its industry average P/E of 21.55x. The company has a Return on Equity (ROE) of 17.66% and a debt-to-equity ratio of 2.96.

HPC Biosciences Ltd Share Price Chart — NSE/BSE Historical Performance

No data
High
284.45
Low
214.90
Volume
7.8K
Change
+9.95%

HPC Biosciences Ltd share price chart: 9.95% return over the past month. 52-week high ₹284.45, 52-week low ₹140.10.

HPC Biosciences Ltd — Last 10 Trading Days

DateOpenHighLowCloseVolume
250.00250.00240.55248.00361.00 (Cr)
251.50259.00249.00250.006.48K (Cr)
260.00260.00250.95251.508.69K (Cr)
250.00265.30247.05264.1513.49K (Cr)
261.45261.45250.00252.7012.13K (Cr)
250.00262.65246.75249.904.48K (Cr)
242.05252.45242.05250.151.69K (Cr)
242.00246.45230.00244.451.51K (Cr)
249.35254.70236.90237.6010.29K (Cr)
244.40254.00244.00249.352.06K (Cr)

HPC Biosciences Ltd — Last 12 Months Price History

MonthOpenHighLowCloseChange
251.50259.00240.55248.00-1.39%
267.00284.45230.00251.50-5.81%
158.10278.50158.00267.05+68.91%
180.10190.00158.00158.10-12.22%
153.15199.85142.30179.10+16.94%
170.00186.00140.10153.85-9.50%
200.95200.95156.10172.20-14.31%
155.05206.50150.00192.50+24.15%
160.15194.45150.00163.55+2.12%
170.10180.00157.50166.00-2.41%
200.40215.95165.65171.45-14.45%
170.00215.35163.50206.45+21.44%

AI Research Briefing

Powered by Gemini · 2026-04-13

High-risk micro-cap leveraged to Indian packaging growth, but financials and past behavior raise serious concerns.

Research Confidence
5.0/10Moderate
MICRO-CAP DARK HORSE1M: 16.94%, 3M: 12.5%, 6M: 19.53% [cite: brief] - showing positive momentum.P/E of 14.07x is lower than the industry P/E of 21.55x [cite: brief], but this may be justified given the risks.

WHAT'S HAPPENING NOW (last 2-4 weeks)

No major catalysts found after live search. The most recent news relates to the broader packaging industry and not HPC Biosciences specifically.

CORE STORY (THE REAL GAME)

Why Now
  • Indian packaging industry growth
  • Strong YoY profit growth [cite: brief]
  • Shift towards organized retail and e-commerce
Potential Catalysts
  • Significant order wins
  • Debt reduction
  • Improvement in FCF
Key Risks
  • Micro/SME cap - liquidity risk
  • High Debt/Equity ratio of 2.96 [cite: brief]
  • Negative Free Cash Flow of ₹-171.58 Cr over 5 years [cite: brief]
Institutional Activity

FII increased stake to 4.5% (Δ 4.43%) [cite: brief]. DII holding steady at 4.8% (Δ 0.0%) [cite: brief]. Promoter holding remains high at 75% [cite: brief].

Macro Context

The Indian packaging industry is projected to grow strongly, driven by rising consumption and e-commerce.

Cash Flow Quality

Profit not converting to cash. Free Cash Flow 5Y: ₹-171.58 Cr [cite: brief]

3–6 Month Outlook

If HPC Biosciences can manage its debt and capitalize on industry growth, there is potential for significant upside. However, the risks are substantial, and a turnaround is not guaranteed.

Primary Thesis Risk

Inability to service debt amidst slowing growth could lead to collapse.

For educational purposes only. Not investment advice. Consult a SEBI-registered advisor before investing.

Returns & Performance

Good

Return on Equity (ROE)

17.66%

Profit generated per ₹1 of shareholder equity

Poor

Return on Capital (ROCE)

13.23%

Returns generated on total capital deployed

Poor

Oper. Profit Margin (5Y Avg)

5.83%

Average operating profit margin over 5 years

Dividend Yield

0.52%

Annual dividend as % of current share price

HPC Biosciences Ltd Valuation Check

Excellent

Price to Earnings (P/E)

14.07x

Share price ÷ earnings per share. Lower = cheaper

Poor

Industry Avg P/E

21.55x

Average P/E of all peers in this sector

Market-cap Classification
Small-cap
Higher growth potential with higher volatility.

Shareholding Pattern

Excellent

Promoter Holding

75.00%

% shares held by company founders/management

Poor

FII Holding

4.50%

% shares held by foreign institutional investors

Poor

DII Holding

4.80%

% held by domestic mutual funds, LIC, banks

Excellent

Promoter Pledged %

0.00%

% of promoter shares pledged as collateral — lower is safer

Growth Engine

Excellent

Profit Growth (Quarterly YoY)

164.00%

Net profit growth vs same quarter last year

Excellent

Revenue Growth (Quarterly YoY)

68.86%

Revenue growth vs same quarter last year

Revenue Growth (5-Year CAGR)

N/A

Compounded annual revenue growth over 5 years

EPS Growth (5-Year CAGR)

N/A

Earnings per share growth over 5 years

Net Profit Growth (5-Year CAGR)

N/A

Compounded annual net profit growth over 5 years

Balance Sheet Health

Poor

Debt to Equity Ratio

2.96x

Total debt ÷ equity. Below 0.5 = financially healthy

Average

Interest Coverage Ratio

2.73x

EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably

Free Cash Flow (5-Year Total)

-171.58 (Cr)

Cash left after capex over 5 years. Positive = self-funded growth

Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice

HPC Biosciences Ltd Fundamental Analysis & Valuation Benchmarking

Educational evaluation of HPBL across key market metrics for learning purposes.

Positive Indicators

6 factors identified

Strong Return on Equity (17.66%)

Observation: Efficient use of shareholders' capital generating superior returns.

Analysis: ROE >15% indicates strong profitability and effective management. This metric suggests the company can generate substantial returns on invested capital.

Attractive Valuation (P/E: 14.07 vs Industry: 21.55)

Observation: Trading at discount to industry peers.

Analysis: P/E below industry average may present value opportunity.

Robust Profit Growth (164.00%)

Observation: Strong year-over-year profit expansion demonstrates business momentum.

Analysis: Profit growth >20% indicates effective execution and market opportunity capture.

Strong Revenue Growth (68.86%)

Observation: Healthy sales growth indicates market demand and execution capability.

Analysis: Revenue growth >15% suggests strong market position and growth potential.

Balanced Promoter Holding (75.00%)

Observation: Optimal balance between promoter control and public float.

Analysis: Promoter holding in 50-75% range provides management alignment.

Zero Share Pledging Risk

Observation: No promoter shares pledged as collateral.

Analysis: Absence of share pledging eliminates potential forced-selling pressure.

Risk Factors

3 factors identified

Elevated Debt Levels (D/E: 2.96)

Observation: High leverage increases financial risk and interest burden.

Analysis: High debt-to-equity ratios require monitoring of debt servicing capability.

Negative Free Cash Flow (₹-171.58 Cr over 5Y)

Observation: Cash outflows exceed inflows.

Analysis: Negative FCF requires analysis of capital expenditure cycle.

Limited Institutional Interest (FII+DII: 9.30%)

Observation: Low institutional participation may affect liquidity.

Analysis: Limited institutional interest may indicate size constraints or visibility issues.

HPC Biosciences Ltd vs Packaging Peers

Peer Comparison - Packaging

Compare HPC Biosciences Ltd with 10 other companies in the same sector

11 companies
Company Info
Fundamental
Valuation
Profitability
Financial Health
Growth
Dividend
Company
Company name
Score
Bull Run comprehensive fundamental score based on 20+ metrics
Price
Current trading price of the stock
Market Cap
Total value of all shares in the market
P/E
Price per share divided by earnings per share
ROE
Net income divided by shareholder equity
ROCE
Earnings before interest and tax divided by capital employed
Debt/Eq
Total debt divided by total equity
Profit 5Y
Average annual profit growth over 5 years
Sales 5Y
Average annual sales growth over 5 years
Dividend
Annual dividend per share divided by price per share
39.9/100
248
₹204.16
14.1
Average
17.66%
Good
13.23%
Average
3.0
Poor
0.52%
EPL Ltd...
EPL500135
44.7/100
215
₹6584.98
15.8
Average
16.27%
Good
17.48%
Good
0.3
Excellent
11.09%
Good
8.82%
Good
2.43%
55.6/100
587
₹5009.58
14.2
Average
16.24%
Good
19.89%
Good
0.2
Excellent
46.54%
Excellent
6.35%
Good
0.91%
33.9/100
410
₹3479.97
11.0
Average
3.29%
Poor
7.75%
Poor
1.2
Average
-8.05%
Poor
15.22%
Excellent
0.62%
50.4/100
2658
₹2883.06
23.1
Average
23.84%
Excellent
20.03%
Excellent
1.0
Good
30.97%
Excellent
13.78%
Good
0.95%
0/100
904
₹2595.83
35.4
Average
5.72%
Poor
7.16%
Poor
0.2
Excellent
-3.71%
Poor
8.94%
Good
1.63%
33.1/100
1090
₹2361.41
174.5
Average
6.56%
Poor
7.93%
Poor
0.5
Excellent
138.26%
Excellent
8.56%
Good
0.20%
13/100
705
₹2235.40
40.9
Average
2.15%
Poor
5.36%
Poor
1.1
Average
-28.49%
Poor
8.52%
Good
1.15%
28.7/100
687
₹2076.53
30.9
Average
9.81%
Poor
12.41%
Average
0.3
Excellent
8.41%
Good
12.30%
Good
0.64%
37.1/100
748
₹1884.11
12.9
Average
9.26%
Poor
9.77%
Poor
1.1
Average
2.84%
Average
5.61%
Good
0.56%
9.1/100
25
₹1783.71
148.0
Average
24.70%
Excellent
15.77%
Good
2.6
Poor
0.00%

HPC Biosciences Ltd Quarterly Performance

Latest quarterly metrics for HPBL — revenue growth and profit growth vs same quarter last year

Revenue Growth (YoY)

68.86%

Latest quarter vs same quarter previous year

Net Profit Growth (YoY)

164.00%

Latest quarter net profit vs same quarter previous year

5-Year Revenue CAGR

N/A

Compounded annual revenue growth over 5 years

5-Year Profit CAGR

N/A

Compounded annual net profit growth over 5 years

HPC Biosciences Ltd Technical Indicators

SMA 50, SMA 200, RSI and volume signals for HPBL — calculated from daily price history

43RSI 14
Neutral — RSI 43

Momentum is balanced — neither overbought nor oversold.

SMA 50
214
▲ Price above SMA 50 — Short-term bullish
SMA 200
185
▲ Price above SMA 200 — Long-term uptrend
30-Day Avg Volume
9K shares/day
Average daily traded volume over last 30 trading sessions

Technical indicators are for educational purposes only. Not investment advice.

HPC Biosciences Ltd Financial Statements

Annual income statement, balance sheet and cash flow for HPC Biosciences Ltd (HPBL) — sourced from NSE/BSE filings.

Loading Financial Statements...

Fetching financial data for HPC Biosciences Ltd

About HPBL (HPC Biosciences Ltd)

HPC Biosciences Ltd is a pioneer in the design and manufacture of innovative packaging solutions tailored for the demanding needs of the biopharmaceutical industry. HPBL specialize...s in developing and producing high-performance containers and delivery systems, focusing on maintaining the integrity and efficacy of sensitive biological materials. Their product line encompasses a range of temperature-controlled packaging, including insulated shippers and phase change material (PCM) solutions, ensuring consistent and reliable temperature maintenance throughout the cold chain. Furthermore, HPBL is committed to sustainable practices, exploring biodegradable and recyclable materials to minimize environmental impact. They offer customized packaging solutions designed to meet specific product requirements, including various sizes, formats, and security features, guaranteeing product safety and security during transportation and storage. HPBL's core expertise lies in its ability to combine advanced materials science with precision engineering, producing packaging that exceeds industry standards. Their innovative approach includes integrating real-time monitoring capabilities, allowing for complete visibility of the package's environmental conditions throughout its journey. This integration of technology ensures that clients can track temperature, humidity, and other critical parameters, facilitating informed decision-making and mitigating potential risks. HPBL places a strong emphasis on research and development, consistently pushing the boundaries of packaging technology. They are dedicated to providing reliable and cost-effective solutions that address the evolving challenges faced by the biopharmaceutical sector. HPBL distinguishes itself through its commitment to quality and regulatory compliance, adhering to the most stringent global standards, including those set by the World Health Organization (WHO) and the International Safe Transit Association (ISTA). Their manufacturing processes are meticulously controlled, utilizing state-of-the-art equipment and employing rigorous quality assurance measures. HPBL works in close collaboration with its clients, providing technical support and expert guidance to ensure optimal packaging performance. This collaborative approach extends from initial design concepts to final product delivery, fostering long-term partnerships built on trust and mutual success. HPBL aspires to be the preeminent provider of packaging solutions, empowering the biopharmaceutical industry to deliver life-saving therapies worldwide.

Company Details

Symbol:HPBL
Industry:Packaging
Sector:Packaging

Key Leadership

Mr. Prakash Hiralal Parekh
MD & Executive Director
Jagdeep Singh Rana
Vice President
Mr. Dhrumil Pranavkumar Shah
Chief Financial Officer

Corporate Events

Recent
Ex-Dividend Date

HPBL Share Price: Frequently Asked Questions

What is the current share price of HPC Biosciences Ltd?

HPC Biosciences Ltd (HPBL) trades at ₹248.00 on NSE and BSE. Market cap ₹204.16 (Cr). Educational data only.

What is the P/E ratio of HPC Biosciences Ltd?

HPC Biosciences Ltd has a P/E of 14.07x vs industry average 21.55x.

What is the Bull Run score for HPC Biosciences Ltd?

HPC Biosciences Ltd has a Bull Run score of 39.9/100 based on 25+ financial parameters.

Does HPC Biosciences Ltd pay dividends?

HPC Biosciences Ltd has a dividend yield of 0.52%. Past dividends don't guarantee future payments.

What is the ROE of HPC Biosciences Ltd?

HPC Biosciences Ltd has ROE of 17.66%. Higher ROE indicates better use of shareholder equity.

What is the debt-to-equity ratio of HPC Biosciences Ltd?

HPC Biosciences Ltd has debt-to-equity of 2.96.

Is HPC Biosciences Ltd a good investment?

Bull Run gives HPC Biosciences Ltd a score of 39.9/100. This is not investment advice — consult a SEBI-registered advisor.